TG Therapeutics Compagnie réclamée
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. Lire la suite
HR or Marketing? Claim Your Free Employer Account
Working together is better then working against one another.
Qu’est-ce qui ne va pas et comment cela peut-il être amélioré?
There shouldn't be any nepotism
Other Employee Reviews for TG Therapeutics
×